EGC Therapeutics, Inc. Recognized as Compliant with Clinical GMP (2025-07-31)
작성자 관리자
날짜 2026-09-11 17:42:00
As of July 23, 2025, EGC Therapeutics, Inc. obtained recognition of conformity with the Good Manufacturing Practice standards for medical devices in the field of dental bone graft materials from the Ministry of Food and Drug Safety. (Clinical GMP)
We are pursuing the world's first commercialization of a whitlockite synthetic bone graft material with outstanding bone regeneration performance. Unlike conventional calcium phosphate-based synthetic bone graft materials, the whitlockite synthetic bone graft material contains magnesium within its molecular structure, and therefore has a more effective bone regeneration mechanism by controlling both osteogenic and osteoclastic activity.
Building on this recognition of Clinical GMP compliance, we are proceeding with clinical trials. If the clinical trials are successfully completed, we will achieve the distinction of being the first in the world to obtain product approval for a whitlockite synthetic bone graft material and bring it to market. Many hurdles still remain ahead, but our executives and employees will devote our best efforts to ensure that this commercialization succeeds.
Thank you.